ThirtyFiveBio
Private Company
Total funding raised: $4.5M
Overview
ThirtyFiveBio is a preclinical-stage biotech developing first-in-class GPR35 inhibitors as a novel, orthogonal treatment for ulcerative colitis (UC). The company's science is built on human genetic validation and a patient-centric biology approach, targeting the protection of the gut epithelium to address a core disease mechanism not tackled by current anti-inflammatory therapies. With a preclinical candidate selected and a patent portfolio filed, the company is advancing through late preclinical activities and is targeting clinical proof-of-mechanism by 2028. It is seeking a syndicated Series A financing round in the second half of 2025 to fund this translation.
Technology Platform
Specialist drug discovery platform focused on genetically-validated GPR35 biology, utilizing patient data and patient-derived models to develop oral small molecule antagonists.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
The ulcerative colitis market is crowded with established anti-TNFs, integrin inhibitors, IL-23 inhibitors, and JAK inhibitors. ThirtyFiveBio's differentiation lies in its unique epithelial shield mechanism targeting GPR35, a genetically-validated target. While other GPR35 programs may exist, the company's specific patient-led biology approach and preclinical progress could provide a competitive edge in this novel niche.